Phase 3, Randomized, Double-Blind Trial Of Pembrolizumab Plus Epacadostat Or Placebo For Cisplatin-Ineligible Urothelial Carcinoma (Uc): Keynote-672/Echo-307.
JOURNAL OF CLINICAL ONCOLOGY(2018)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2018)